Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AGRI dumped most of.19s kept a few as usual
IBIO nice play not saying it won’t go higher .. .common warrants to purchase up to 5,287,278 shares of common stock at a purchase price of $2.85 per share (or pre-funded warrant in lieu thereof), subject to certain beneficial ownership limitations set by each holder. The warrants issued in the offering are exercisable six (6) months upon issuance at an exercise price of $2.64 per share and will expire five years from the date of issuance
Real estate markets getting worse and worse. Not investable until bottom in.
Texas' Housing Market Tumbles
Published Mar 13, 2024 at 12:16 PM EDT
Updated Mar 15, 2024 at 7:00 AM EDT
00:53
By Giulia Carbonaro
US News Reporter
FOLLOW
6
Home sales in Texas fell to the lowest level in seven years…
Real estate markets getting obliterated with un affordability. Of course mainstream media not reporting at all.
Texas' Housing Market Tumbles
Published Mar 13, 2024 at 12:16 PM EDT
Updated Mar 15, 2024 at 7:00 AM EDT
00:53
By Giulia Carbonaro
US News Reporter
FOLLOW
6
Home sales in Texas fell to the lowest level in seven years….
IBIO 2.70s all out of trade warrant price 2.60s
VERB .43 dump some at .44 perhaps which it hit last news release. Doing quick flip here myself keep only 10%
VERB .38 News VERB's MARKET.live Enters Into Formal Partnership With TikTok for Livestream Shopping Services
Source: GlobeNewswire Inc.
Verb Technology Company, Inc. (Nasdaq: VERB) ("VERB" or the "Company"), the force behind MARKET.live, the popular livestream social shopping platform, announces it has entered into a formal partnership with TikTok Shop pursuant to which MARKET.live has become a service provider for TikTok Shop and is officially designated as a TikTok Shop Partner (TSP). Under the terms of the partnership, TikTok Shop refers consumer brands, retailers, influencers and affiliates leads to Market.live for a menu of paid services that include, among other things, assistance in onboarding to TikTok and establishing a TikTok store, hosting training sessions and webinars for prospective TikTok Shop sellers, studio space rental in both the West Coast and East Coast MARKET.live studios, content creation and production services, and TikTok Shop maintenance, including enhancements to existing TikTok Shop seller stores. The partnership also contemplates TikTok Shop sponsored studio rentals, as well as a paid-for “day pass” for use of MARKET.live studio services by TikTok creators, influencers and affiliates. MARKET.live will generate revenue through fees, including monthly recurring fees, paid directly to MARKET.live by the brands, retailers, influencers and affiliates referred to MARKET.live by TikTok. In addition, it is contemplated that MARKET.live will receive a percentage of monthly revenue generated through the TikTok stores MARKET.live establishes for the brands, retailers, influencers and affiliates that TikTok Shop refers to MARKET.live.
The partnership also contemplates the use of MARKET.live studios as TikTok “Sample Centers” where TikTok creators will have access to product samples for use in their TikTok Shop videos produced at MARKET.live studios. In addition to the compensation referenced above, TikTok will compensate MARKET.live directly for the attainment of certain pre-established performance goals and objectives agreed-to between the parties.
This formal partnership underscores a shared commitment to enriching the livestream shopping experience on the TikTok platform. As TSP partners, MARKET.live and TikTok align their visions to expand and enhance ecommerce capabilities, recognizing the transformative potential of livestream shopping in today's digital landscape. TikTok is leveraging MARKET.live’s expertise in this pivotal role as a TSP partner in which MARKET.live will provide guidance and support for the brands, vendors, and creators that seek to utilize TikTok Shop. Market.live will help these sellers navigate the intricate terrain of setup, content creation, and live streaming on TikTok Shop through a choice of comprehensive pricing packages encompassing shop operations, performance marketing, affiliate management, live stream production, and content creation, empowering brands and creators to thrive in the dynamic world of livestream shopping.
The parties are planning a series of co-hosted events, similar to the Miami Music Week event hosted by MARKET.live for TikTok brands and influencers in Miami last week on March 21, 2024. Building on this momentum, MARKET.live and TikTok are co-hosting an exclusive event on April 25, 2024 to announce the partnership. Attendance is by invitation only and restricted to brands, creators, affiliates, industry executives, and other invited guests. This event promises to showcase the latest trends in livestream shopping and foster meaningful connections within the industry. Interested parties can request an invitation at this link.
“We see very clearly the future of livestream shopping in the US and MARKET.live’s important place in that future,” states Rory J. Cutaia, VERB CEO. “This is an extraordinary business building relationship we have developed with TikTok and our team is committed to working hard to exceed all expectations, notwithstanding the fact that those expectations are running pretty high right now.”
For more information, please visit MARKET.live or follow the latest updates on social media.
ERB's MARKET.live Enters Into Formal Partnership With TikTok for Livestream Shopping Services
Source: GlobeNewswire Inc.
Verb Technology Company, Inc. (Nasdaq: VERB) ("VERB" or the "Company"), the force behind MARKET.live, the popular livestream social shopping platform, announces it has entered into a formal partnership with TikTok Shop pursuant to which MARKET.live has become a service provider for TikTok Shop and is officially designated as a TikTok Shop Partner (TSP). Under the terms of the partnership, TikTok Shop refers consumer brands, retailers, influencers and affiliates leads to Market.live for a menu of paid services that include, among other things, assistance in onboarding to TikTok and establishing a TikTok store, hosting training sessions and webinars for prospective TikTok Shop sellers, studio space rental in both the West Coast and East Coast MARKET.live studios, content creation and production services, and TikTok Shop maintenance, including enhancements to existing TikTok Shop seller stores. The partnership also contemplates TikTok Shop sponsored studio rentals, as well as a paid-for “day pass” for use of MARKET.live studio services by TikTok creators, influencers and affiliates. MARKET.live will generate revenue through fees, including monthly recurring fees, paid directly to MARKET.live by the brands, retailers, influencers and affiliates referred to MARKET.live by TikTok. In addition, it is contemplated that MARKET.live will receive a percentage of monthly revenue generated through the TikTok stores MARKET.live establishes for the brands, retailers, influencers and affiliates that TikTok Shop refers to MARKET.live.
The partnership also contemplates the use of MARKET.live studios as TikTok “Sample Centers” where TikTok creators will have access to product samples for use in their TikTok Shop videos produced at MARKET.live studios. In addition to the compensation referenced above, TikTok will compensate MARKET.live directly for the attainment of certain pre-established performance goals and objectives agreed-to between the parties.
This formal partnership underscores a shared commitment to enriching the livestream shopping experience on the TikTok platform. As TSP partners, MARKET.live and TikTok align their visions to expand and enhance ecommerce capabilities, recognizing the transformative potential of livestream shopping in today's digital landscape. TikTok is leveraging MARKET.live’s expertise in this pivotal role as a TSP partner in which MARKET.live will provide guidance and support for the brands, vendors, and creators that seek to utilize TikTok Shop. Market.live will help these sellers navigate the intricate terrain of setup, content creation, and live streaming on TikTok Shop through a choice of comprehensive pricing packages encompassing shop operations, performance marketing, affiliate management, live stream production, and content creation, empowering brands and creators to thrive in the dynamic world of livestream shopping.
The parties are planning a series of co-hosted events, similar to the Miami Music Week event hosted by MARKET.live for TikTok brands and influencers in Miami last week on March 21, 2024. Building on this momentum, MARKET.live and TikTok are co-hosting an exclusive event on April 25, 2024 to announce the partnership. Attendance is by invitation only and restricted to brands, creators, affiliates, industry executives, and other invited guests. This event promises to showcase the latest trends in livestream shopping and foster meaningful connections within the industry. Interested parties can request an invitation at this link.
“We see very clearly the future of livestream shopping in the US and MARKET.live’s important place in that future,” states Rory J. Cutaia, VERB CEO. “This is an extraordinary business building relationship we have developed with TikTok and our team is committed to working hard to exceed all expectations, notwithstanding the fact that those expectations are running pretty high right now.”
For more information, please visit MARKET.live or follow the latest updates on social media.
Progress Software Confirms Bid to Acquire MariaDB for .60
MRDB .44 + 95% .so .55 previous raised to .60 ..The global software company made an offer for all issued and to be issued share capital of MariaDB at 60 cents a share.
Progress Software Confirms Bid to Acquire MariaDB
BCTX 2.83 + 10% low float ..the Company will be presenting three posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10 at San Diego Convention Center, San Diego, CA. The details are listed below.
Poster 1:
Title: Efficacy of Bria-IMT regimen in inducing CNS metastasis regression
Session Title: Phase II Clinical Trials 1
Session Date and Time: Tuesday Apr 9, 2024, 9:00 AM - 12:30 PM PST
Location: Poster Section 49
Poster Board Number: 4
Abstract Presentation Number: CT204
Poster 2:
Title: Efficacy and safety of SV-BR-1-GM after progression on ADC in metastatic breast cancer patients
Session Title: Phase II Clinical Trials 1
Session Date and Time: Tuesday Apr 9, 2024, 9:00 AM - 12:30 PM PST
Location: Poster Section 49
Poster Board Number: 6
Abstract Presentation Number: CT206
Poster 3:
Title: Bria-OTS immunotherapy platform: Harnessing gene-modified tumor cells to reinvigorate the cancer immunity cycle for precision anti-tumor responses
Session Category: Immunology
Session Title: Vaccines, Antigens, and Antigen Presentation 2
Session Date and Time: Wednesday Apr 10, 2024, 9:00 AM - 12:30 PM PST
Location: Poster Section 4
Poster Board Number: 22
Abstract Presentation Number: 6753
Following the presentation, copies of the posters will be posted on https://briacell.com/scientific-publications/.
New price target $10 by Jeffries from $1.40
The Reporting Persons elected to form a group to collectively express their opposition to the K1 Proposal. The communication to the Issuer also stated that the Reporting Persons believed that, given the Irish law requirements for approving a takeover deal and the substantial holdings of the Reporting Persons, the K1 Proposal was not actionable from a practical perspective and the board of directors of the Issuer has a duty to inform the other shareholders of the Issuer. The Reporting Persons indicated that they believe that the K1 Proposal prejudices the Issuer’s position to be able to pursue strategic alternatives that would help the Issuer’s financial position. Prior to the K1 Proposal, the Issuer and RP Ventures LLC were in negotiations with respect to a transaction to restructure all or any material part of the obligations under that certain senior secured promissory note, dated as of October 10, 2023 and amended on January 10, 2024, issued by the Issuer to RP Ventures LLC in the principal amount of $26,500,000, which is currently past due and in default. The Reporting Persons urge the board of directors of the Issuer to take appropriate action to create a path where the Issuer can address its operational and capital needs.
IBIO 1.92 +70% warrants 6 months out….common warrants to purchase up to 5,287,278 shares of common stock at a purchase price of $2.85 per share (or pre-funded warrant in lieu thereof), subject to certain beneficial ownership limitations set by each holder. The warrants issued in the offering are exercisable six (6) months upon issuance at an exercise price of $2.64 per share and will expire five years from the date of issuance.
common warrants to purchase up to 5,287,278 shares of common stock at a purchase price of $2.85 per share (or pre-funded warrant in lieu thereof), subject to certain beneficial ownership limitations set by each holder. The warrants issued in the offering are exercisable six (6) months upon issuance at an exercise price of $2.64 per share and will expire five years from the date of issuance.
MRDB IBIO PAYS TTNP HKIT DJT NUVB
MariaDB PLCMRDB
0.4304 +90.02% 1.08M
Ibio IncIBIO
1.92 +66.96% 3.09M
Paysign IncPAYS
4.17 +23.37% 352.02K
Titan PharmaTTNP
8.46 +16.97% 9.7K
Inspire Veterinary.IVP
0.05 +17.25% 2.36K
Hitek GlobalHKIT
1.69 +19.01% 1.19M
WeTrade Group IncWETG
5.15 +15.47% 0
Trump Media & Tech.DJT
66.06 +13.92% 281.38K
Briacell Therapeut.BCTX
2.87 +13.44% 1.1K
Nuvation Bio IncNUVB
3.26 +13.19% 37.03K
MRDB .55 is the potential buyout target
STKS $4.69 + 17% take out order for Sushi please ..Benihana
MRDB .55 time to exit again…announcing on February 16, 2024 that the third party made a non-binding proposal to the board of directors of the Issuer to acquire all of the issued, and to be issued, share capital of the Issuer at a value of $0.55 per share, in violation of Section 3.4 of that certain Forbearance Agreement, dated as of February 5, 2024 (as amended, restated, supplemented or otherwise modified from time to time, the “Forbearance Agreement”) by and among, the Note Parties, the Holder, and RP Ventures LLC, in its capacity as Agent for the Holder (the “Specified Default”). The Specified Default is in addition to any other default or Events of Default that have occurred and are continuing, including, for the avoidance of doubt, the “Existing Defaults” identified on Exhibit A to the Forbearance Agreement (such events of default, together with the Specified Defaults, the “Existing Defaults”). The Note Parties shall continue to comply with all limitations, restrictions and prohibitions that are effective or otherwise applicable under the Note and the other Notes Documents during the continuance of the Existing Defaults.
How about today news
AGRI .17 picked up a few has nice runs
NVDA down the Nasdaq goes red is a market correction finally coming? Wait and see
SMFL down -10% added some .74s this one low float and runs when you least expect it. Add on any more dips
TELL .60 nice bottom at .50 shooting back eventually to .71-.98 range re test..
IVVD $4
KULR .57 almost hit .60 maybe today later..news Lockheed contract
KULR .40 +89% solid break of .40 and .60s next zone to watch
OPGN 1.02 …1.05 next zone
IVVD 3.80 + 17% perhaps catch some pullbacks again here …The price target is now at $10 per share, up from $4.
07:13 AM EDT, 03/26/2024 (MT Newswires) -- Invivyd (IVVD) received an investment rating upgrade to overweight from equalweight from Morgan Stanley on Tuesday, several days after the biopharmaceutical said its Pemgarda monoclonal antibody received emergency use authorization from the US Food & Drug Administration for the prevention of COVID-19 in adults and adolescents with moderate-to-severe immune compromise.
Morgan Stanley also more than doubled its price target on Invivyd's stock amid the Pemgarda authorization. The price target is now at $10 per share, up from $4.
Invivyd's shares were up 16% at $3.74 each in recent Tuesday pre-market trading. The shares had closed at $3.09 each on Thursday, a day before the FDA authorization was announced.
"FDA granting emergency use of Pemgarda represents [a] significant derisking event allowing IVVD to launch their first [monoclonal antibody] for pre-exposure prophylaxis of COVID," Morgan Stanley's analysts said in a Tuesday note to clients.
The authorization was based on positive immunobridging data from a late-stage trial, the analysts noted, highlighting that the trial demonstrated in vitro neutralizing activity against a range of variants, including the JN.1 variant currently dominant in the US. Morgan Stanley believes this "can be reproduced in an accelerated timeline to address future variants."
Invivyd has an average investment rating of outperform among four analysts polled by Capital IQ. The price targets of three analysts range from $4 to $15.
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
OPGN .86 + 80% next .90 - .92 then 1.05-1.21
MESO $3.28 is resistance would need more volume for $5 next zone maybe over a few days …
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
Source: GlobeNewswire Inc.
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has informed the company that following additional consideration the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application (BLA) for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD).
“We thank the agency for their collaborative approach. The responses and guidance from FDA are clear and provide us with a high level of confidence to refile our BLA for remestemcel-L in children with SR-aGVHD,” said Mesoblast CEO Dr. Silviu Itescu.
Mesoblast intends to file the resubmission during the next quarter, seeking to address all remaining product characterization issues.
About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
STOK $11.86 + 80% Cash out time here also catch back $8-$10 perhaps for another round
OPGN .84 cash out time at .90s for sure or now. Nice one
STOK $12.48 +’90% treated with STK-001. Data from these studies showed clinically meaningful effects, including substantial and durable reductions in convulsive seizure frequency and improvements in multiple measures of cognition and behavior that support the potential for disease modification. These improvements were observed among a highly refractory group of patients who were already taking the best available anti-seizure medicines. STK-001 has been generally well-tolerated in studies to date.
Today, the Company also announced clearance from the U.S. Food and Drug Administration (FDA) that allows patients to receive three doses of 70mg followed by continued dosing at 45mg. Based on this regulatory update and these data, the Company plans to meet with regulatory agencies to discuss a registrational study that includes initial doses of 70mg followed by continued dosing at 45mg.
SGMO warrants exercisable in 6 months
STOK CHEK OPGN CISS MESO XTLB INTJ.. Stoke TherapeuticsSTOK
12.15 +86.92% 711.8K
Check Cap LtdCHEK
2.93 +51.81% 1.4M
OpGen IncOPGN
0.63 +32.63% 1.42M
Eterna Therapeutic.ERNA
2.99 +32.30% 0.01K
C3is IncCISS
0.045 +27.14% 47.74M
Mesoblast LtdMESO
2.64 +20.00% 637.76K
Collective Audienc.CAUD
0.80 +15.88% 0
XTL BiopharmaXTLB
3.25 +15.66% 313.25K
Monopar Therapeuti.MNPR
0.819 +15.35% 0
IntelligentINTJ
2.17 +12.44%
Little morning pump then just wait again
NKGN 2.01 -11% nice dip opportunity Alzheimer’s
KULR .40 +89% solid break of .40 and .60s next zone to watch
Ok TSVT still holding flipped some more VHAI again ..95 but still holding some
KULR .35 + 60% hod .39